-
In a sample of patients from primary care practice, a single screening question accurately identified drug use.
-
Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
-
A new three-drug antihypertensive pill, combining an angiotensin II receptor antagonist (olmesartan [OLM]), a calcium channel blocker (amlodipine [AML]), and a thiazide diuretic (hydrochlorothiazide [HCTZ]), has been approved by the FDA. The new combination is marketed by Daiichi Sankyo as Tribenzor.
-
Vital exhaustion predicts long-term risk for adverse cardiac events in men and women, independent of established biomedical risk factors.
-
-
Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
-
A great debate continues regarding appropriate management of hypertension during acute stroke. In the U.S., permissive hypertension is popular with recommendations that antihypertensive medications be discontinued when an acute ischemic stroke occurs.
-
-
Concern about serotonin syndrome should not prevent migraineurs who have mood disorders from being treated judiciously with the combination of triptans and serotonergic medications.
-
Confocal microscopy of the cornea may be a useful diagnostic test to identify patients with small-fiber neuropathies.